Zai Lab (NASDAQ:ZLAB) Director Richard Gaynor Purchases 1,228 Shares of Company Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Richard Gaynor acquired 1,228 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average price of $27.19 per share, with a total value of $33,389.32. Following the completion of the acquisition, the director directly owned 81,965 shares of the company’s stock, valued at $2,228,628.35. This represents a 1.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zai Lab Stock Down 5.5%

NASDAQ:ZLAB traded down $1.44 during mid-day trading on Friday, reaching $24.60. The company’s stock had a trading volume of 1,224,327 shares, compared to its average volume of 1,295,968. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $29.02. The stock has a fifty day moving average of $24.62 and a 200-day moving average of $21.26. The firm has a market capitalization of $3.08 billion, a PE ratio of -13.74 and a beta of 0.77.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. The business had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million. On average, analysts expect that Zai Lab Limited Unsponsored ADR will post -2.19 earnings per share for the current year.

Zai Lab News Summary

Here’s some of the latest news about ZLAB:

• Positive Sentiment: Five Zai Lab medicines were included in China’s 2026 National Reimbursement Drug List: KarXT and VYVGART Hytrulo® for the first time, plus three renewals covering oncology and infectious-disease treatments. Broader reimbursement could improve patient access and support commercial growth, though the reports do not specify the financial impact or reimbursement pricing. Article: Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo in China’s 2026 National Reimbursement Drug List
• Positive Sentiment: Director Richard Gaynor bought 1,228 shares at an average $27.19, increasing his position by 1.52%. The purchase may be viewed as a modest confidence signal. SEC filing: Director share purchase
• Neutral Sentiment: Management is scheduled to attend two London investor conferences later in November; no new financial or clinical disclosures were included in the announcement. Article: Zai Lab Announces Participation in Investor Conferences

Institutional Investors Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. raised its position in shares of Zai Lab by 106.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock valued at $7,743,000 after purchasing an additional 151,883 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in Zai Lab by 65.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock worth $8,692,000 after purchasing an additional 130,000 shares in the last quarter. Seven Fleet Capital Management LP grew its position in Zai Lab by 74.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after purchasing an additional 58,158 shares during the last quarter. Headlands Technologies LLC grew its position in Zai Lab by 142.0% during the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after purchasing an additional 39,901 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in Zai Lab by 34.9% during the 3rd quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after purchasing an additional 38,562 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

ZLAB has been the subject of a number of recent research reports. Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Citigroup increased their target price on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zai Lab presently has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Zai Lab Company Profile

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.